185 related articles for article (PubMed ID: 28082400)
1. ARF Confers a Context-Dependent Response to Chemotherapy in Muscle-Invasive Bladder Cancer.
Owczarek TB; Kobayashi T; Ramirez R; Rong L; Puzio-Kuter AM; Iyer G; Teo MY; Sánchez-Vega F; Wang J; Schultz N; Zheng T; Solit DB; Al-Ahmadie HA; Abate-Shen C
Cancer Res; 2017 Feb; 77(4):1035-1046. PubMed ID: 28082400
[TBL] [Abstract][Full Text] [Related]
2. An Oncofetal Glycosaminoglycan Modification Provides Therapeutic Access to Cisplatin-resistant Bladder Cancer.
Seiler R; Oo HZ; Tortora D; Clausen TM; Wang CK; Kumar G; Pereira MA; Ørum-Madsen MS; Agerbæk MØ; Gustavsson T; Nordmaj MA; Rich JR; Lallous N; Fazli L; Lee SS; Douglas J; Todenhöfer T; Esfandnia S; Battsogt D; Babcook JS; Al-Nakouzi N; Crabb SJ; Moskalev I; Kiss B; Davicioni E; Thalmann GN; Rennie PS; Black PC; Salanti A; Daugaard M
Eur Urol; 2017 Jul; 72(1):142-150. PubMed ID: 28408175
[TBL] [Abstract][Full Text] [Related]
3. JUND-dependent up-regulation of HMOX1 is associated with cisplatin resistance in muscle-invasive bladder cancer.
Peng Y; Chen Y; Chen S; Wang J; Jiang C; Hou W; Xu C
J Biochem; 2020 Jul; 168(1):73-82. PubMed ID: 32240302
[TBL] [Abstract][Full Text] [Related]
4. Correlation of p53, MDM2 and p14(ARF) protein expression in human esophageal squamous cell carcinoma.
Cheng TH; Hsu PK; Li AF; Hung IC; Huang MH; Hsu HS
J Cancer Res Clin Oncol; 2009 Nov; 135(11):1577-82. PubMed ID: 19488782
[TBL] [Abstract][Full Text] [Related]
5. Human p14(Arf): an exquisite sensor of morphological changes and of short-lived perturbations in cell cycle and in nucleolar function.
David-Pfeuty T; Nouvian-Dooghe Y
Oncogene; 2002 Oct; 21(44):6779-90. PubMed ID: 12360404
[TBL] [Abstract][Full Text] [Related]
6. The expression profile of p14, p53 and p21 in tumour cells is associated with disease-specific survival and the outcome of postoperative chemotherapy treatment in muscle-invasive bladder cancer.
Aljabery F; Shabo I; Gimm O; Jahnson S; Olsson H
Urol Oncol; 2018 Dec; 36(12):530.e7-530.e18. PubMed ID: 30539751
[TBL] [Abstract][Full Text] [Related]
7. TAp73 expression and P1 promoter methylation, a potential marker for chemoresponsiveness to cisplatin therapy and survival in muscle-invasive bladder cancer (MIBC).
Bunch B; Krishnan N; Greenspan RD; Ramakrishnan S; Attwood K; Yan L; Qi Q; Wang D; Morrison C; Omilian A; Bshara W; Pili R; Trump DL; Johnson C; Woloszynska A
Cell Cycle; 2019 Sep; 18(17):2055-2066. PubMed ID: 31318640
[TBL] [Abstract][Full Text] [Related]
8. Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy.
Pietzak EJ; Zabor EC; Bagrodia A; Armenia J; Hu W; Zehir A; Funt S; Audenet F; Barron D; Maamouri N; Li Q; Teo MY; Arcila ME; Berger MF; Schultz N; Dalbagni G; Herr HW; Bajorin DF; Rosenberg JE; Al-Ahmadie H; Bochner BH; Solit DB; Iyer G
Eur Urol; 2019 Feb; 75(2):231-239. PubMed ID: 30290956
[TBL] [Abstract][Full Text] [Related]
9. p14(ARF) regulates E2F activity.
Mason SL; Loughran O; La Thangue NB
Oncogene; 2002 Jun; 21(27):4220-30. PubMed ID: 12082609
[TBL] [Abstract][Full Text] [Related]
10. Profiles of the 2 INK4a gene products, p16 and p14ARF, in human reference urothelium and bladder carcinomas, according to pRb and p53 protein status.
Le Frère-Belda MA; Gil Diez de Medina S; Daher A; Martin N; Albaud B; Heudes D; Abbou CC; Thiery JP; Zafrani ES; Radvanyi F; Chopin D
Hum Pathol; 2004 Jul; 35(7):817-24. PubMed ID: 15257544
[TBL] [Abstract][Full Text] [Related]
11. p14ARF is a component of the p53 response following ionizing irradiation of normal human fibroblasts.
Khan S; Guevara C; Fujii G; Parry D
Oncogene; 2004 Aug; 23(36):6040-6. PubMed ID: 15195142
[TBL] [Abstract][Full Text] [Related]
12. Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer.
Plimack ER; Dunbrack RL; Brennan TA; Andrake MD; Zhou Y; Serebriiskii IG; Slifker M; Alpaugh K; Dulaimi E; Palma N; Hoffman-Censits J; Bilusic M; Wong YN; Kutikov A; Viterbo R; Greenberg RE; Chen DY; Lallas CD; Trabulsi EJ; Yelensky R; McConkey DJ; Miller VA; Golemis EA; Ross EA
Eur Urol; 2015 Dec; 68(6):959-67. PubMed ID: 26238431
[TBL] [Abstract][Full Text] [Related]
13. Different requirements for the cytostatic and apoptotic effects of type I interferons. Induction of apoptosis requires ARF but not p53 in osteosarcoma cell lines.
Sandoval R; Xue J; Pilkinton M; Salvi D; Kiyokawa H; Colamonici OR
J Biol Chem; 2004 Jul; 279(31):32275-80. PubMed ID: 15169789
[TBL] [Abstract][Full Text] [Related]
14. p16INK4a and p14ARF methylation as a potential biomarker for human bladder cancer.
Kawamoto K; Enokida H; Gotanda T; Kubo H; Nishiyama K; Kawahara M; Nakagawa M
Biochem Biophys Res Commun; 2006 Jan; 339(3):790-6. PubMed ID: 16316628
[TBL] [Abstract][Full Text] [Related]
15. p14(ARF) nuclear overexpression in aggressive B-cell lymphomas is a sensor of malfunction of the common tumor suppressor pathways.
Sánchez-Aguilera A; Sánchez-Beato M; García JF; Prieto I; Pollan M; Piris MA
Blood; 2002 Feb; 99(4):1411-8. PubMed ID: 11830494
[TBL] [Abstract][Full Text] [Related]
16. Adenovirus-mediated overexpression of p14(ARF) induces p53 and Bax-independent apoptosis.
Hemmati PG; Gillissen B; von Haefen C; Wendt J; Stärck L; Güner D; Dörken B; Daniel PT
Oncogene; 2002 May; 21(20):3149-61. PubMed ID: 12082630
[TBL] [Abstract][Full Text] [Related]
17. Platinum Concentration and Pathologic Response to Cisplatin-Based Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer.
Guancial EA; Kilari D; Xiao GQ; Abu-Farsakh SH; Baran A; Messing EM; Kim ES
PLoS One; 2016; 11(5):e0155503. PubMed ID: 27187160
[TBL] [Abstract][Full Text] [Related]
18. Human p14(ARF)-mediated cell cycle arrest strictly depends on intact p53 signaling pathways.
Weber HO; Samuel T; Rauch P; Funk JO
Oncogene; 2002 May; 21(20):3207-12. PubMed ID: 12082636
[TBL] [Abstract][Full Text] [Related]
19.
Li Q; Damish AW; Frazier Z; Liu D; Reznichenko E; Kamburov A; Bell A; Zhao H; Jordan EJ; Gao SP; Ma J; Abbosh PH; Bellmunt J; Plimack ER; Lazaro JB; Solit DB; Bajorin D; Rosenberg JE; D'Andrea AD; Riaz N; Van Allen EM; Iyer G; Mouw KW
Clin Cancer Res; 2019 Feb; 25(3):977-988. PubMed ID: 29980530
[TBL] [Abstract][Full Text] [Related]
20. INK4a-ARF alterations and p53 mutations in hepatocellular carcinomas.
Tannapfel A; Busse C; Weinans L; Benicke M; Katalinic A; Geissler F; Hauss J; Wittekind C
Oncogene; 2001 Oct; 20(48):7104-9. PubMed ID: 11704835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
